IO102-IO103 (Cylembio®) + pembrolizumab
First-line Advanced Melanoma
Key Facts
Indication
First-line Advanced Melanoma
Phase
Phase 3
Status
Completed - New registrational study being designed
Company
About IO Biotech
IO Biotech is developing a new class of therapeutic cancer vaccines based on its proprietary T-win® technology, which targets immune-suppressive molecules like IDO1 and PD-L1. The company's lead candidate, IO102-IO103 (Cylembio®), has shown promising clinical activity in combination with anti-PD-1 therapy in advanced melanoma. Following a strategic review and recent corporate restructuring, IO Biotech is exploring strategic alternatives to advance its pipeline.
View full company profile